drugset / Trial / NCT07275749
Acetyl-leucine in Post-stroke Ataxia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Along with the current clinical trial, the efficacy and safety of 4 gram of acetyl-leucine daily for three months in patients with post-stroke ataxia following posterior-circulation ischaemic stroke assessed through BBS, SARA, and mRS, and possible adverse effects.
Timeline
- Start
- 2025-12-01
- Primary completion
- 2026-07-01
- Completion
- 2026-07-20
Publications
- Results Paciaroni M, Ince B, Hu B, Jeng JS, Kutluk K, Liu L, Lou M, Parfenov V, Wong KSL, Zamani B, Paek D, Min Han J, Del Aguila M, Girotra S. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. Cardiovasc Ther. 2019 Dec 1;2019:1607181. doi: 10.1155/2019/1607181. eCollection 2019.
- Results Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia. 2003 Jul;23(6):441-50. doi: 10.1046/j.1468-2982.2003.00546.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acetyl-Leucine | Small molecule | 4 g | — |
| Comparator | Aspirin | Small molecule | 100 mg | — |
| Comparator | Clopidogrel | Small molecule | 75 mg | Oral |